The epigenetic modifiers 5-aza-29-deoxycytidine and trichostatin A influence adipocyte differentiation in human mesenchymal stem cells

Brazilian Journal of Medical and Biological Research

Volumn 46, Issue 5, 2013, Pages 405-416

  Zych, J ^a   Stimamiglio, M A ^a   Senegaglia, A C ^b   Brofman, P R S ^b   Dallagiovanna, B ^a   Goldenberg, S ^a   Correa, A ^a  

^a INSTITUTO CARLOS CHAGAS   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

5 Aza 29 deoxycytidine; Adipocyte differentiation; Epigenetics; Mesenchymal stem cells; Trichostatin A

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BONE MORPHOGENETIC PROTEIN 4; DESMIN; FATTY ACID BINDING PROTEIN 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR GATA 2; TRICHOSTATIN A;

ADIPOCYTE; ADIPOGENESIS; ADULT; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DNA CONTENT; DOWN REGULATION; EPIGENETICS; FLOW CYTOMETRY; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MESENCHYMAL STEM CELL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 84878458974     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20132893     Document Type: Article

References (40)

1. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317, doi: 10.1080/14653240600855905.
2. Liu TM, Martina M, Hutmacher DW, Hui JH, Lee EH, Lim B. Identification of common pathwaysmediating differentiation of bone marrow-and adipose tissue-derived human mesenchymal stem cells into three mesenchymal lineages. Stem Cells 2007; 25: 750-760, doi: 10.1634/stemcells.2006-0394.
3. Meshorer E, Misteli T. Chromatin in pluripotent embryonic stem cells and differentiation. Nat Rev Mol Cell Biol 2006; 7: 540-546, doi: 10.1038/nrm1938.
4. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705, doi: 10.1016/j.cell.2007.02.005.
5. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370: 737-749, doi: 10.1042/BJ20021321.
6. Taddei A, Roche D, Bickmore WA, Almouzni G. The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep 2005; 6: 520-524, doi: 10.1038/sj.embor.7400441.
7. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5: 981-989, doi: 10.1158/1541-7786.MCR-07-0324.
8. Kim SN, Choi HY, Kim YK. Regulation of adipocyte differentiation by histone deacetylase inhibitors. Arch Pharm Res 2009; 32: 535-541, doi: 10.1007/s12272-009-1409-5.
9. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001; 293: 1068-1070, doi: 10.1126/science.1063852.
10. Christman JK. 5-Azacytidine and 5-aza-29-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002; 21: 5483-5495, doi: 10.1038/sj.onc.1205699.
11. Kim K, Zhao R, Doi A, Ng K, Unternaehrer J, Cahan P, et al. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol 2011; 29: 1117-1119, doi: 10.1038/nbt.2052.
12. Rebelatto CK, Aguiar AM, Moretao MP, Senegaglia AC, Hansen P, Barchiki F, et al. Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue. Exp Biol Med 2008; 233: 901-913, doi: 10.3181/0712-RM-356.
13. Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 2006; 7: 885-896, doi: 10.1038/nrm2066.
14. Chen G, Deng C, Li YP. TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 2012; 8: 272-288, doi: 10.7150/ijbs.2929.
15. Feng SW, Chen F, Cao J, Yu MJ, Liang YY, Song XM, et al. Restoration of muscle fibers and satellite cells after isogenic MSC transplantation with microdystrophin gene delivery. Biochem Biophys Res Commun 2012; 419: 1-6, doi: 10.1016/j.bbrc.2012.01.029.
16. Cristancho AG, Lazar MA. Forming functional fat: a growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol 2011; 12: 722-734, doi: 10.1038/nrm3198.
17. Liang W, Xia H, Li J, Chunhua ZR. 5-Aza-29-deoxycytidine increases the sensitivity of human bone marrow mesenchymal stem cells to chemotherapeutic agents by demethylation of p73. J Pediatr Hematol Oncol 2012; 34: 108-115.
18. Arney KL, Fisher AG. Epigenetic aspects of differentiation. J Cell Sci 2004; 117: 4355-4363, doi: 10.1242/jcs.01390.
19. Wu H, Sun YE. Epigenetic regulation of stem cell differentiation. Pediatr Res 2006; 59: 21R-25R, doi: 10.1203/01.pdr.0000203565.76028.2a.
20. Mattout A, Meshorer E. Chromatin plasticity and genome organization in pluripotent embryonic stem cells. Curr Opin Cell Biol 2010; 22: 334-341, doi: 10.1016/j.ceb.2010.02.001.
21. Meshorer E, Yellajoshula D, George E, Scambler PJ, Brown DT, Misteli T. Hyperdynamic plasticity of chromatin proteins in pluripotent embryonic stem cells. Dev Cell 2006; 10: 105-116, doi: 10.1016/j.devcel.2005.10.017.
22. Yoo EJ, Chung JJ, Choe SS, Kim KH, Kim JB. Downregulation of histone deacetylases stimulates adipocyte differentiation. J Biol Chem 2006; 281: 6608-6615, doi: 10.1074/jbc.M508982200.
23. Lagace DC, Nachtigal MW. Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis. J Biol Chem 2004; 279: 18851-18860, doi: 10.1074/jbc.M312795200.
24. Lee S, Park JR, Seo MS, Roh KH, Park SB, Hwang JW, et al. Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells. Cell Prolif 2009; 42: 711-720, doi: 10.1111/j.1365-2184.2009.00633.x.
25. El-Serafi AT, Oreffo RO, Roach HI. Epigenetic modifiers influence lineage commitment of human bone marrow stromal cells: Differential effects of 5-aza-deoxycytidine and trichostatin A. Differentiation 2011; 81: 35-41, doi: 10.1016/j.diff.2010.09.183.
26. Hagiwara H, Saito F, Masaki T, Ikeda M, Nakamura-Ohkuma A, Shimizu T, et al. Histone deacetylase inhibitor trichostatin A enhances myogenesis by coordinating muscle regulatory factors and myogenic repressors. Biochem Biophys Res Commun 2011; 414: 826-831, doi: 10.1016/ j.bbrc.2011.10.036.
27. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004; 338: 17-31, doi: 10.1016/j.jmb.2004.02.006.
28. Hayakawa F, Towatari M, Ozawa Y, Tomita A, Privalsky ML, Saito H. Functional regulation of GATA-2 by acetylation. J Leukoc Biol 2004; 75: 529-540, doi: 10.1189/jlb.0603289.
29. Orlic D, Anderson S, Biesecker LG, Sorrentino BP, Bodine DM. Pluripotent hematopoietic stem cells contain high levels of mRNA for c-kit, GATA-2, p45 NF-E2, and c-myb and low levels or no mRNA for c-fms and the receptors for granulocyte colony-stimulating factor and interleukins 5 and 7. Proc Natl Acad Sci U S A 1995; 92: 4601-4605, doi: 10.1073/pnas.92.10.4601.
30. Tong Q, Dalgin G, Xu H, Ting CN, Leiden JM, Hotamisligil GS. Function of GATA transcription factors in preadipocyteadipocyte transition. Science 2000; 290: 134-138, doi: 10.1126/science.290.5489.134.
31. Ozawa Y, Towatari M, Tsuzuki S, Hayakawa F, Maeda T, Miyata Y, et al. Histone deacetylase 3 associates with and represses the transcription factor GATA-2. Blood 2001; 98: 2116-2123, doi: 10.1182/blood.V98.7.2116.
32. Komashko VM, Farnham PJ. 5-azacytidine treatment reorganizes genomic histone modification patterns. Epigenetics 2010; 5: 229-240, doi: 10.4161/epi.5.3.11409.
33. Menendez L, Walker D, Matyunina LV, Dickerson EB, Bowen NJ, Polavarapu N, et al. Identification of candidate methylation-responsive genes in ovarian cancer. Mol Cancer 2007; 6: 10, doi: 10.1186/1476-4598-6-10.
34. Araki H, Yoshinaga K, Boccuni P, Zhao Y, Hoffman R, Mahmud N. Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential. Blood 2007; 109: 3570-3578, doi: 10.1182/blood-2006-07-035287.
35. Sakamoto H, Kogo Y, Ohgane J, Hattori N, Yagi S, Tanaka S, et al. Sequential changes in genome-wide DNA methylation status during adipocyte differentiation. Biochem Biophys Res Commun 2008; 366: 360-366, doi: 10.1016/ j.bbrc.2007.11.137.
36. Guo W, Zhang KM, Tu K, Li YX, Zhu L, Xiao HS, et al. Adipogenesis licensing and execution are disparately linked to cell proliferation. Cell Res 2009; 19: 216-223, doi: 10.1038/cr.2008.319.
37. Muruganandan S, Roman AA, Sinal CJ. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol Life Sci 2009; 66: 236-253, doi: 10.1007/s00018-008-8429-z.
38. Hupkes M, Jonsson MK, Scheenen WJ, van Rotterdam W, Sotoca AM, van Someren EP, et al. Epigenetics: DNA demethylation promotes skeletal myotube maturation. FASEB J 2011; 25: 3861-3872, doi: 10.1096/fj.11-186122.
39. Davidson S, Crowther P, Radley J, Woodcock D. Cytotoxicity of 5-aza-29-deoxycytidine in a mammalian cell system. Eur J Cancer 1992; 28: 362-368, doi: 10.1016/ S0959-8049(05)80054-1.
40. Meissner A. Epigenetic modifications in pluripotent and differentiated cells. Nat Biotechnol 2010; 28: 1079-1088, doi: 10.1038/nbt.1684.